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1  | INTRODUC TION
The novel corona virus infection (now classified as COVID-19), first 
identified in December 2019 in Wuhan, China, has contributed to 
significant mortality in several countries with the number of in-
fected cases increasing exponentially worldwide.1 The majority of 
the most severely ill patients initially present with single organ fail-
ure (ie, respiratory insufficiency) but some of them progress to more 
systemic disease and multiple organ dysfunction. One of the most 
significant poor prognostic features in those patients is the develop-
ment of coagulopathy.2 In patients who develop sepsis from various 
infectious agents, development of coagulopathy is one of the key 
and persistent features which is associated with poor outcomes.3 
In this context, the role of International Society of Thrombosis and 
Haemostasis (ISTH) will be crucial in guiding health-care profes-
sionals in how to manage the coagulopathy of COVID-19. A simple 
and easily followable algorithm for the management of COVID-19 
coagulopathy would currently be useful in both the well-resourced 
and less-resourced settings as a guide in managing this complica-
tion. This pragmatic statement should clearly be considered as an 
interim guidance because the clinical experience of managing this 
pandemic is increasing. The authors are certain that this statement 
will be modified with developing knowledge and therapeutics in 
managing COVID-19. The aim of this guidance document is to pro-
vide a risk stratification at admission for a COVID-19 patient and 
management of coagulopathy which may develop in some of these 
patients, based on easily available laboratory parameters.
2  | COAGUL ATION MARKERS AT 
ADMISSION
One of the key issues recognized with the management of COVID-
19 infection has been the very high volume of patients presenting 
to health centers or hospitals. It clearly overwhelms the human and 
mechanistic capacities available, in particular the need for critical care 
support. As such, risk stratification measures would clearly be helpful. 
Currently, this is based on the clinical characteristics of severe pneu-
monia and a consistent finding of lymphopenia in most patients.4
In addition, one of the most common laboratory findings noted in 
COVID-19 patients requiring hospitalization has been the increase in 
D-dimers.3 It is already well established that older individuals and those 
who have co-morbidities (both groups tend to have higher D-dimer) 
are more likely to die from COVID-19 infection. In the largest analysis 
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of clinical cases published to date, which included data regarding 1099 
patients with laboratory-confirmed COVID-19 from more than 550 
hospitals in China, a D-dimer ≥0.5 mg/L was noted in 260/560 (46.4%) 
patients tested with only 43% having raised D-dimer if the disease 
was non-severe, and about 60% had severe illness.2 In a study specifi-
cally looking at abnormal coagulation parameters, Tang and colleagues 
have identified markedly elevated D-dimers as one of the predic-
tors of mortality.3 They noted a presentation D-dimer of 2.12 μg/mL 
(range 0.77-5.27 μg/mL) in the non-survivors while it was 0.61 μg/mL 
(range 0.35-1.29 μg/mL) in the survivors with the lab normal ranges of 
<0.50 μg/mL.3 Similarly, Huang and colleagues showed D-dimer level 
on admission were higher in patients needing critical care support (me-
dian D-dimer level 2.4 mg/L [0.6-14.4]) than those patients who did 
not require it (median D-dimer level 0.5 mg/L [0.3-0.8], P = .0042).1 For 
these reasons, the patients who have markedly raised D-dimers (which 
may be arbitrarily defined as three- to four-fold increase), admission 
to hospital should be considered even in the absence of other severe 
symptoms because this clearly signifies increased thrombin generation.
The other diagnostic tests commonly performed in any sick pa-
tient are the prothrombin time (PT), and the platelet count. In the 
Tang study, PT was also prolonged in the non-survivors at admission 
but only rather modestly (15.5 seconds [range 14.4–16.3 seconds] 
in non-survivors versus 13.6 seconds [13.0-14.3 seconds] in survi-
vors; normal range [11.5−14.5 seconds]).3 The PT was also mildly 
prolonged at admission in those who needed critical care support 
versus the non-ICU cohort (12.2 seconds [range 11.2–13.4] versus 
10.7 seconds [range 9.8–12.1], respectively).1 Of note, it is likely that 
such subtle changes will not be picked up if the prothrombin time 
is reported as international normalized ratio (INR), which occurs in 
many centers (INR is not the same as PT ratio).
Thrombocytopenia is often considered an indicator of sepsis mor-
tality.5 Interestingly, this is not the case at admission in many of the 
COVID-19 patients. In the study of 41 patients published in the Lancet, 
a platelet count less than 100 × 109/L was only seen in 2/40 (5%) pa-
tients with one each in ICU and non-ICU category while <150 × 109/L 
was seen in 38/40 (95%) with similar numbers needing or not needing 
critical care support.1 On admission, thrombocytopenia determined as 
150 × 109/L was also noted in 36.2% in the largest series but further 
subclassification was not given although while 31.6% of the patients 
had non-severe illness, 57.7% had severe illness.2 A meta-analysis of 
nine studies including COVID-19 patients with nearly 400 with se-
vere disease identified that the platelet count was significantly lower 
in patients with more severe COVID-19 (weighted mean difference 
−31 × 109/L; 95% confidence interval [CI], from −35 to −29 × 109/L).6 
Subgroup analysis comparing patients by survival noted lower plate-
let count correlated with mortality. Thrombocytopenia was also asso-
ciated with over five-fold increased risk of severe COVID-19 illness 
(odds ratio [OR], 5.1; 95% CI, 1.8-14.6). This suggests thrombocytope-
nia at the time of admission may be but not consistent prognosticator.
Based on the currently available literature, we would recommend 
measuring D-dimers, prothrombin time, and platelet count (in decreas-
ing order of importance) in all patients who present with COVID-19 
infection. This may help in stratifying patients who may need admission 
and close monitoring or not (see Figure 1). Any underlying condition 
(eg, liver disease) or medication (eg, anticoagulants) which may alter the 
parameters should be accounted for while using the algorithm.
3  | MONITORING COAGUL ATION 
MARKERS
It is common practice in most critical care units to monitor hemo-
static markers to identify worsening coagulopathy. In addition to 
the platelet count, PT, and D-dimers, it may be useful to measure 
fibrinogen in this scenario, as recommended by the ISTH guidance 
on disseminated intravascular coagulation (DIC).7 With respect to 
COVID-19 infection, this is an area which has not yet been well stud-
ied except by Tang et al.3 They noted the development of DIC on day 
4 in the 71.4% of patients who did not survive the infection com-
pared to DIC in just one patient (0.6%) who survived. The research-
ers also noted a statistically significant increase in D-dimer levels, 
and PT, and decrease in fibrinogen levels in non-survivors at days 
10 and 14. This establishes the huge importance of regular labora-
tory monitoring in these patients. They also observed a decrease in 
antithrombin levels in the non-survivors although this test cannot be 
undertaken easily in many laboratories.
Based on this study and the experience from published literature 
on septic coagulopathy, monitoring PT, D-dimer, platelet count, and 
fibrinogen can be helpful in determining prognosis in COVID-19 pa-
tients requiring hospital admission.8-10 If there is worsening of these 
parameters, more aggressive critical care support is warranted and 
consideration should be given for more “experimental” therapies and 
blood product support as appropriate. If these markers are stable or 
improving, it gives the added confidence for stepdown of treatment 
if corroborating with the clinical condition.
4  | MANAGEMENT OF COVID -19 
COAGULOPATHY
This section is based on the only currently available evidence that 
markedly increased D-dimer is associated with high mortality in 
COVID-19 patients. It is also based on the evidence that multi-organ 
failure is more likely in patients with sepsis if they develop coagulop-
athy and inhibiting thrombin generation may have benefit in reduc-
ing mortality.11,12 The only widely available treatment in this respect 
is prophylactic dose low molecular weight heparin (LMWH), which 
should be considered in all patients (including non-critically ill) who 
require hospital admission for COVID-19 infection, in the absence of 
any contraindications (active bleeding and platelet count less than 
25 × 109/L; monitoring advised in severe renal impairment; abnormal 
PT or activated partial thromboplastin time [APTT] is not a contrain-
dication). The benefit of this approach has recently been submitted 
as an abstract by Dr Ning Tang. The study included 449 patients with 
severe COVID-19, of which 99 received heparin (mainly with LMWH) 
at prophylactic doses. Although no difference was observed in the 
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28-day mortality in those who received heparin compared to those 
who did not, if a SIC (sepsis-induced coagulopathy) score ≥4 were to 
be applied to the patients, anticoagulant therapy with LMWH ap-
pears to be associated with better prognosis in relation to mortal-
ity (40.0% versus 64.2%, P = .029).13 A similar benefit was noted in 
those with D-dimer >six-fold of upper limit of normal (32.8% versus 
52.4%, P = .017). LMWH will also protect critically ill patients against 
venous thromboembolism. In addition, LMWH has been shown to 
have anti-inflammatory properties which may be an added benefit 
in COVID infection where pro-inflammatory cytokines are markedly 
raised.1,2,14
Bleeding is rare in the setting of COVID-19. If bleeding does de-
velop, similar principles to septic coagulopathy as per the harmonized 
ISTH guidelines with respect to blood transfusions may be followed7 
(see Figure 1). There are several other therapies for COVID-19 which 
can only be considered experimental at the moment including anti-
thrombin supplementation, recombinant thrombomodulin, and hy-
droxychloroquine based on mitigating the excess thrombin generation 
hypothesis and immunosuppressive agents including inhalational 
therapies which may put a check on the “immunothrombosis” model 
(bidirectional relationship between inflammation and thrombosis).
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F I G U R E  1   Algorithm for the management of coagulopathy in COVID-19 based on simple laboratory markers. * The list of markers is 
given in decreasing order of importance. ** Performing fibrinogen assays may not be feasible in many laboratories but monitoring the levels 
can be helpful after patient admission. *** Although a specific cut-off cannot be defined, a three- to four-fold increase in D-dimer values may 
be considered significant. Any one of the values in this table may be considered significant
1. D-dimer*
2. Prothrombin time
3. Platelet count
4. Fibrinogen**
1. D-dimer markedly raised*** 
2. Prothrombin time prolonged
3. Platelet count <100 × 109/L  
4. Fibrinogen <2.0 g/L
Admit (even if no other concerns)  
Monitor once or twice daily
1. D-dimer not markedly raised  
2. Prothrombin time normal 
3. Platelet count normal  
4. Fibrinogen elevated
If admitted for other clinical reasons,
Monitor daily 
If discharged, use as baseline for
if re-presenting with symptoms
Start prophylactic dose 
low molecular weight heparin
Blood products as per protocol (see box on the right)
Consider experimental therapies
In non-bleeding patients, keep 
platelet count above 25 × 109/L  
In bleeding patients, keep 
platelet count above 50 × 109/L
fibrinogen above 1.5 g/L 
PT ratio <1.5 (not the same as INR)
Worsening
In all patients
Please discuss with transfusion services 
in view of likely blood scarcity
4  |     THACHIL eT AL.
 3. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are 
associated with poor prognosis in patients with novel coronavirus 
pneumonia. J Thromb Haemost. 2020;18(4):844-847
 4. Zhang J, Zhou L, Yang Y, Peng W. Therapeutic and triage strategies 
for 2019 novel coronavirus disease in fever clinics. Lancet. 2019. 
https://doi.org/10.1016/S2213 -2600(20)30071 -0
 5. Williamson DR, Albert M, Heels-Ansdell D, et al. Thrombocytopenia 
in critically ill patients receiving thromboprophylaxis. Chest. 
2013;144(4):1207-1215.
 6. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated 
with severe coronavirus disease 2019 (COVID-19) infections: A me-
ta-analysis. Clin Chim Acta. 2020;8981(20):145-148.
 7. Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and 
treatment of DIC from harmonization of the recommendations 
from three guidelines. The Scientific Standardization Committee 
on DIC of the International Society on Thrombosis Haemostasis. 
J Thromb Haemost. 2013. https://doi.org/10.1111/jth.12155
 8. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, 
clinical and laboratory criteria, and a scoring system for disseminated 
intravascular coagulation. Thromb Haemost. 2001;86:1327-1330.
 9. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and 
management of disseminated intravascular coagulation. British Committee 
for Standards in Haematology. Br J Haematol. 2009;145:24-33.
 10. di Nisio M, Baudo F, Cosmi B, et al. Diagnosis and treatment of disseminated 
intravascular coagulation: Guidelines of the Italian Society for Haemostasis 
and Thrombosis (SISET). Thromb Res. 2012;129(5):e177-e184.
 11. Shankar-Hari M, Phillips GS, Levy ML, et al. Sepsis definitions task 
force. Developing a new definition and assessing new clinical crite-
ria for septic shock: for the third international consensus definitions 
for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):775-787.
 12. Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of 
sepsis-induced coagulopathy and disseminated intravascular coag-
ulation. J Thromb Haemost. 2019;17(11):1989-1994.
 13. Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for 
sepsis-induced coagulopathy (SIC) following the revised sepsis defi-
nition: a retrospective analysis of a nationwide survey. BMJ Open. 
2017;7(9):e017046.
 14. Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagu-
lant: do heparins have direct anti-inflammatory effects? Thromb 
Haemost. 2017;117(3):437-444.
